Drug Infusion System Market is Anticipated to Grow At a Significant CAGR of 8.89% and Will Reach Upto USD 18.05 Billion by 2026, Asserts DelveInsight
Drug Infusion System market is contemplated to surge in the coming years due to factors such as rising prevalence of chronic disorders such as cardiovascular disorders along with an increasing prevalence of cancers, there is an increase in the demand for Drug Infusion Systems observed, thus driving the growth of Drug Infusion System market.
Las Vegas, USA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Drug Infusion System Market is Anticipated to Grow At a Significant CAGR of 8.89% and Will Reach Upto USD 18.05 Billion by 2026, Asserts DelveInsight
Drug Infusion System market is contemplated to surge in the coming years due to factors such as rising prevalence of chronic disorders such as cardiovascular disorders along with an increasing prevalence of cancers, there is an increase in the demand for Drug Infusion Systems observed, thus driving the growth of Drug Infusion System market.
DelveInsight's Drug Infusion System Market Insights and Forecast report provides the current and forecast Drug Infusion System, upcoming innovation in the devices, individual market shares of the devices, challenges, drivers and barriers, market trends, and key competitors in the Drug Infusion System.
Some of the essential takeaways from the Drug Infusion System Market report:
According to DelveInsight analysis, North America is expected to dominate the overall Drug Infusion System Market during the forecast period.
Key pharma players proactively working in the Drug Infusion System market include B. Braun Melsungen AG, Medtronic, BD, PROMECON GmbH, Arcomed Ag, Fresenius Kabi AG, Microport Scientific Corporation, Teleflex Incorporated., Smiths Medical, Baxter, Ivenix Inc, Terumo Corporation, Insulet Corporation., FLOWONIX MEDICAL INC, Intera Oncology and others.
As per DelveInsight estimates, the Global Drug Infusion System was valued at USD 10.83 billion in 2020 and is anticipated to grow at a massive CAGR of 8.89% during the forecast period from 2021 to 2026 and is also expected to reach USD 18.05 billion by 2026.
On August 09, 2021, Smiths Medical and Ivenix had announced their partnership pertaining to best-in-class infusion management technologies for improving the infusion delivery process.
On July 22, 2021, Innovative Health Sciences had announced the CE mark for syringe infusion system.
On April 26, 2021, Becton Dickinson and Company had announced FDA approval for BD Alaris System.
On May 20, 2020, Baxter had announced the CE Marking and Australian regulatory approval for Evo IQ Syringe Infusion System.
To pick on the latest highlights related to the Drug Infusion System Market get the snapshot of the key highlights entailed in the Drug Infusion System Market report.
A Drug Infusion System is a medical pump that tends to deliver fluids, nutrients, and medications into the body of the patient in precise amounts. Drug Infusion System is used in hospitals, nursing homes, and in the homes. The Drug Infusion System tend to offer several advantages over manual administration of fluids, comprising of the ability for delivering fluids in very small volumes and the potential for delivering fluids at précised programming rates or automated intervals. It tends to deliver nutrients or medications, for instance, inulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers.
Interested in knowing how the Drug Infusion System Market will be growing by 2026? Click to get a snapshot of Drug Infusion System Market Landscape
Drug Infusion System Market Insight
Geographically, the global Drug Infusion System market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America tends to lead the global Drug Infusion System market in the present scenario and is expected that it will continue to remain superior during the forecast period. However, the domination exhibited by North America will be
conspicuously challenged by the European market. This domination in North America is attributed to the rising prevalence of chronic conditions such as cardiovascular disorders and type 2 diabetes, growing prevalence of obesity, favorable reimbursement policies, and the presence of all major key players in the North American market.
Also, there are great opportunities for Drug Infusion System market penetration for Asia Pacific regions as the major companies already have a grip in developed regions. Further, due to the increase in prevalence of diabetes and the presence of key players in Asia-Pacific regions, there is an increasing demand observed for Drug Infusion System in these regions, thereby positively influencing the overall drug infusion system market.
On June 11, 2019, Ivenix had announced FDA approval for Ivenix Infusion System. The design had been made for offering infusions safely while reducing the total cost of ownership.
On April 04, 2019, FDA approval was granted to Avanos Medical’s ON-Q Bolus pump, a device that allows patients that are suffering from pain management after surgery for drug infusion.
Understand more about the Drug Infusion System Market Landscape @ Drug Infusion System Analysis
Drug Infusion System Market Drivers and Barriers
The rising prevalence of cancers, rising prevalence of chronic conditions such as cardiovascular disorders and type 2 diabetes, growing prevalence of obesity, there will be an increase in the demand of Drug Infusion System for the delivery of drugs, thereby leading to an increase in the Drug Infusion System market. In addition to that, recent development such as product launches, technologically
advanced Drug Infusion System is also driving the market growth further. Other aspects such as market development related to products, expansions, and mergers and acquisitions there will be a significant growth in Drug Infusion System market during the forecast period.
To get a deeper understanding of the driving factors related to the Drug Infusion System market, get a snapshot of the Drug Infusion System Market Dynamics
Drug Infusion System market had observed a period of stagnant growth owing to the outbreak of COVID-19 since 2020. Due to the COVID-19 pandemic situation, all the other forms of elective procedures were temporarily stopped in contrast to the COVID-19 affected patients that were given utmost priority. Other factors such as lockdown restrictions, patient reluctance to visit the hospitals and clinics, logistical restrictions, unavailability of medical devices and the closing down of manufacturing facilities can all be considered as potential setbacks for Drug Infusion System market.
To gain a better understanding of the COVID-19 impact on the Drug Infusion System, get a snapshot of the Drug Infusion System Market Assessment
Scope of the Drug Infusion System Market Report
Study Period: 2018-2026
Key Drug Infusion System Companies: B. Braun Melsungen AG, Medtronic, BD, PROMECON GmbH, Arcomed Ag, Fresenius Kabi AG, Microport Scientific Corporation, Teleflex Incorporated., Smiths Medical, Baxter, Ivenix Inc, Terumo Corporation, Insulet Corporation., FLOWONIX MEDICAL INC, Intera Oncology and others.
Drug Infusion System Market Segmentation
By Product Type
Syringe Infusion Systems
Elastomeric Infusion Systems
Large-Volume Infusion Systems
Enteral Infusion Systems
PCA Infusion Systems
Insulin Pumps
Others
By Product Placement
External
Implantable
By Portability
Stationary
Ambulatory
By Application
Oncotherapy
Diabetes
Analgesia
Nutrition
Others
By End-User
Hospitals
Ambulatory Surgical Centers
Homecare Settings
Others
By Geography
North America
Europe
Asia-Pacific
Rest of the World
Delveinsight Analysis: The Drug Infusion System market is expected to grow at a CAGR of 8.89% and will reach 18.05 billion by 2026.
Table of Contents
1 | Drug Infusion System Market Report Introduction |
2 | Drug Infusion System Market Executive Summary |
3 | Regulatory and Patent Analysis |
4 | Drug Infusion System Market Key Factors Analysis |
5 | Drug Infusion System Market Porter’s Five Forces Analysis |
6 | COVID-19 Impact Analysis on Drug Infusion System Market |
7 | Drug Infusion System Market Layout |
8 | Drug Infusion System Market Global Company Share Analysis – Key 3-5 Companies |
9 | Drug Infusion System Company and Product Profiles |
9.1 BD | |
10 | Project Approach |
11 | KOL Views |
12 | DelveInsight Capabilities |
13 | Disclaimer & Contact Us |
14 | About DelveInsight |
Learn more about the report offerings @ Drug Infusion System Market Outlook
Discover more about the Medical Devices Reports to diagnose, prevent and cure various diseases, along with key players developing several devices to drive the treatment market.
Related Reports
Intranasal Drug Delivery Market
The Global Intranasal Drug Delivery Market was valued at USD 43.28 billion in 2020, growing at a CAGR of 6.29% during the forecast period from 2021 to 2026, to reach USD 62.36 billion by 2026. The report delivers in-depth understanding and the historical and forecasted market trends, market drivers, market barriers and key companies like AFT Pharmaceuticals, AptarGroup, Inc., SaNOtize Research & Development Corp., Becton, Dickinson and Company, Oyster Point Pharma, Inc., Impel Neuropharma, Teleflex Incorporated, SipNose, Kurve Technology, Inc, Mystic Pharmaceuticals, Medica Holdings, LLC, 3M Company, Neurelis, Inc., PENDOPHARM, GlaxoSmithKline. Cipla, Glenmark Pharmaceuticals, Novartis AG, AstraZeneca, Johnson & Johnson and others.
"DelveInsight’s ‘Drug-Eluting Stents - Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Drug-Eluting Stents and the historical and forecasted Drug-Eluting Stents market trends, market drivers, market barriers and key companies like Abbott, Braun Melsungen AG, Biosensors International Group, Ltd, BIOTRONIK SE & Co. KG, Boston Scientific Corporation,Terumo Corporation,Medtronic, MicroPort Scientific Corporation, STENTYS SA, Lepu Medical, Cook, Cardinal Health, and others.
Injectable Drug Delivery Devices Market
Global Injectable Drug Delivery Devices Market was valued at USD 17.65 billion in 2020, growing at a CAGR of 11.25% during the forecast period from 2021 to 2026, to reach USD 33.37 billion by 2026. The report delivers in-depth understanding and the historical and forecasted market trends, market drivers, market barriers and key companies like Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Johnson & Johnson, Antares Pharma, AbbVie Inc, Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.
"DelveInsight’s ‘Novel Drug Delivery Devices - Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Novel Drug Delivery Devices and the historical and forecasted Novel Drug Delivery Devices market trends, market drivers, market barriers and key companies.
Transdermal Drug Delivery Devices Market
Transdermal Drug Delivery Devices Market is growing at a CAGR of 9.8% during the forecast period from 2021 to 2026. The report delivers in-depth understanding and the historical and forecasted market trends, market drivers, market barriers and key companies like Hisamitsu Pharmaceutical, Mylan, UCB SA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Johnson & Johnson, Endo International, Purdue Pharma, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Acrux Limited, Lavipharm, Lead Chemicals Co. Inc., Luye Pharma Group, and others.
Transmucosal Drug Delivery Devices Market
"DelveInsight’s ‘Transmucosal Drug Delivery Devices - Market Insight, Competitive Landscape and Market Forecast, 2026’ report delivers an in-depth understanding of Transmucosal Drug Delivery Devices and the historical and forecasted Transmucosal Drug Delivery Devices market trends, market drivers, market barriers and key companies like 3M, Cephalon, Inc, Biopharmaceutical, Antares Pharma., Teva Pharmaceutical Industries Ltd., Slan Medicinal Holdings LTD, MMB Healthcare, LLC, BioDelivery Sciences International, Inc, Mylan N.V., and others.
Browse Through Our Blog Posts
Bayer’s Gadavist MRI agent gets FDA approval to treat adult patients with known or suspected coronary artery disease
The New Buzz of Transcranial Stimulation Devices in the Neurological Disorders Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
